An Open-Label, Dose-Response Study of CM4620 Injectable Emulsion (CM4620-IE) in Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome (SIRS)
Latest Information Update: 09 Dec 2021
At a glance
- Drugs Zegocractin (Primary)
- Indications Pancreatitis; Systemic inflammatory response syndrome
- Focus Adverse reactions
- Sponsors CalciMedica
- 02 Jun 2021 Results presented in a CalciMedica media release.
- 02 Jun 2021 According to a CalciMedica media release, the study published in the journal was led by lead authors Charles Bruen, M.D., and Joseph Miller, M.D.
- 02 Jun 2021 According to a CalciMedica media release, data from this study were published in the peer-reviewed journal Pancreas.